Perrigo Company plc Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
Perrigo Company plc (PRGO) had Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net of $22.70 million as of 2026-03-28, per its 10-Q filed 2026-05-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Disposal Group, Including Discontinued Operation, Assets, Current
us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet · last filed 2026-05-06
- 2026-03-28: Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net $22.70M.
- 2025-12-31: Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net $23.60M.
| Period end | Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net |
|---|---|
| 2026-03-28 | $22.70M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $23.60M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |